THE YEAR IN SHORT

AddLife 2022

The acquisitions of recent years have established AddLife as a European player with operations in multiple niches and geographic markets. 2022 has been a year of change where our companies have demonstrated their ability to take action and continuously adapt to changing market conditions. The companies have proven to be reliable and competent partners that offer customers high delivery reliability even in times of major changes and uncertainty in deliveries and logistics flows. In summary, growth amounted to 14%, of which 4% was organic (excluding COVID-19).

As expected, COVID-19-related sales have decreased significantly during the year and have been replaced by acquired growth within Medtech. The COVID-19-related sales had good margins because the additional volumes could be handled by the existing organization without increased costs, while our new acquisitions deliver more normal margins.

The business situation in all markets has been changing throughout the year as the pandemic has subsided. The Labtech companies delivered large amounts of COVID-19 related products at the beginning of the year. In the second half of the year, the effects of the pandemic decreased and regular operations drove growth. The increase in turnover within Medtech is mainly driven by the acquisitions of recent years, which have positioned AddLife well to support customers to meet the large healthcare backlog that has accumulated during the pandemic.​